<DOC>
	<DOC>NCT01239212</DOC>
	<brief_summary>The primary objective of this study is to determine the pharmacokinetic profile of a 50 mg/kg loading dose of intravenous levetiracetam (LEV) in term and late preterm infants with seizures. Secondary objectives are to evaluate the safety and efficacy of a 50 mg/kg loading dose of levetiracetam in term and preterm infants with seizures, and to obtain data on steady state drug levels of levetiracetam in neonates.</brief_summary>
	<brief_title>Dosing of Levetiracetam (Keppra) in Neonates</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Gestational age ≥ 32 weeks Postnatal age ≤ 30 days Birth weight ≥ 2000 grams Admitted to the Neonatal Intensive Care Unit at Cincinnati Children's Hospital Clinical or electrographic seizures of any etiology Seizures or seizure prophylaxis requiring treatment with levetiracetam Parental consent obtained Infants with renal insufficiency indicated by serum creatinine &gt; 2.0 at any time Infants who have previously received levetiracetam Parents refuse consent Attending physician does not wish the infant to be enrolled in the study Infants who are currently receiving an investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Days</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>seizures</keyword>
	<keyword>neonate</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>central nervous system diseases</keyword>
	<keyword>anticonvulsants</keyword>
</DOC>